Advertisement

De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence

  • Benedetta Conte
    Affiliations
    Department of Medical Oncology, Breast Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
    Search for articles by this author
  • Davide Soldato
    Affiliations
    Predictive Biomarkers and New Therapeutic Strategies in Oncology, Gustave Roussy, Villejuif, France

    Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
    Search for articles by this author
  • Maria Grazia Razeti
    Affiliations
    Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
    Search for articles by this author
  • Piero Fregatti
    Affiliations
    Department of Surgical Sciences and Integrated Diagnostic (DISC), University of Genoa, Genoa, Italy

    Breast Surgery Clinic, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
    Search for articles by this author
  • Evandro de Azambuja
    Affiliations
    Institut Jules Bordet and L'Université Libre de Bruxelles (ULB), Brussels, Belgium
    Search for articles by this author
  • Francesco Schettini
    Affiliations
    Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain

    Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
    Search for articles by this author
  • Aleix Prat
    Affiliations
    Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain

    Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain

    Department of Medicine, University of Barcelona, Barcelona, Spain
    Search for articles by this author
  • Lucia Del Mastro
    Affiliations
    Department of Medical Oncology, Breast Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

    Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa, Italy
    Search for articles by this author
  • Matteo Lambertini
    Correspondence
    Address for correspondence: Matteo Lambertini, MD PhD, Medical Oncology Department, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, University of Genova, Largo Rosanna Benzi 10, 16132 Genova, Italy, Tel: +39 010 555 4254, Fax: +39 010 555 6536
    Affiliations
    Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

    Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa, Italy
    Search for articles by this author
Published:October 08, 2021DOI:https://doi.org/10.1016/j.clbc.2021.10.001

      Abstract

      Women with metastatic breast cancer remains a heterogeneous group of patients with different prognostic outcomes and therapeutic needs. Young women with de novo metastatic breast cancer (dnMBC) represent a peculiar population with respect to tumor biology, prognosis, clinical management and survivorship issues. Overall, these patients are able to attain long-term survival with a proper management of both primary tumor and distant metastases. On the other hand, they are also at higher risk of experiencing a deterioration in their quality of life (QoL) due to primary cancer-related side effects. Young women are also likely to harbor germline pathogenic variants in cancer predisposition genes which could affect treatment decisions and have a direct impact on the lives of patients’ relatives. The loco-regional management of the primary tumor represents another thorny subject, as the surgical approach has shown controversial effects on the survival and the QoL of these patients.
      This review aims to provide an update on these issues to better inform the clinical management of dnMBC in young women.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Deluche E
        • Antoine A
        • Bachelot T
        • et al.
        Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016.
        Eur J Cancer. 2020; 129: 60-70https://doi.org/10.1016/j.ejca.2020.01.016
        • Dawood S
        • Broglio K
        • Ensor J
        • Hortobagyi GN
        • Giordano SH.
        Survival differences among women with de novo stage IV and relapsed breast cancer.
        Ann Oncol. 2010; 21: 2169-2174https://doi.org/10.1093/annonc/mdq220
        • McKenzie HS
        • Maishman T
        • Simmonds P
        • et al.
        Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients.
        Br J Cancer. 2020; 122: 1618-1629https://doi.org/10.1038/s41416-020-0784-z
        • Malmgren JA
        • Mayer M
        • Atwood MK
        • Kaplan HG.
        Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010.
        Breast Cancer Res Treat. 2018; 167: 579-590https://doi.org/10.1007/s10549-017-4529-5
        • Frank S
        • Carton M
        • Dubot C
        • et al.
        Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort.
        Breast. 2020; 52: 50-57https://doi.org/10.1016/j.breast.2020.04.009
        • Vaz-Luis I
        • Lin NU
        • Keating NL
        • Barry WT
        • Winer EP
        • Freedman RA.
        Factors associated with early mortality among patients with de novo metastatic breast cancer: a population-based study.
        Oncologist. 2017; 22: 386-393https://doi.org/10.1634/theoncologist.2016-0369
        • Zhao W
        • Wu L
        • Zhao A
        • et al.
        A nomogram for predicting survival in patients with de novo metastatic breast cancer: a population-based study.
        BMC Cancer. 2020; 20: 982https://doi.org/10.1186/s12885-020-07449-1
        • Anders CK
        • Hsu DS
        • Broadwater G
        • et al.
        Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
        J Clin Oncol. 2008; 26: 3324-3330https://doi.org/10.1200/JCO.2007.14.2471
        • Partridge AH
        • Hughes ME
        • Warner ET
        • et al.
        Subtype-dependent relationship between young age at diagnosis and breast cancer survival.
        J Clin Oncol. 2016; 34: 3308-3314https://doi.org/10.1200/JCO.2015.65.8013
        • Cardoso F
        • Paluch-Shimon S
        • Senkus E
        • et al.
        5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
        Ann Oncol. 2020; 31: 1623-1649https://doi.org/10.1016/j.annonc.2020.09.010
        • Paluch-Shimon S
        • Cardoso F
        • Partridge AH
        • et al.
        ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4).
        Ann Oncol. 2020; (Published online)https://doi.org/10.1016/j.annonc.2020.03.284
        • Lambertini M
        • Peccatori FA
        • Demeestere I
        • et al.
        Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†.
        Ann Oncol. 2020; 31: 1664-1678https://doi.org/10.1016/j.annonc.2020.09.006
        • Welch HG
        • Gorski DH
        • Albertsen PC.
        Trends in Metastatic Breast and prostate cancer — Lessons in cancer dynamics.
        N Engl J Med. 2015; 373: 1685-1687https://doi.org/10.1056/NEJMp1510443
        • Heller DR
        • Chiu AS
        • Farrell K
        • Killelea BK
        • Lannin DR.
        Why has breast cancer screening failed to decrease the incidence of de novo stage IV disease?.
        Cancers. 2019; 11: 500https://doi.org/10.3390/cancers11040500
        • Brandt J
        • Garne JP
        • Tengrup I
        • Manjer J.
        Age at diagnosis in relation to survival following breast cancer: a cohort study.
        World J Surg Oncol. 2015; 13https://doi.org/10.1186/s12957-014-0429-x
        • Johnson RH
        • Chien FL
        • Bleyer A.
        Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009.
        JAMA. 2013; 309: 800-805https://doi.org/10.1001/jama.2013.776
        • Soares LR
        • Freitas-Junior R
        • Curado MP
        • Paulinelli RR
        • Martins E
        • Oliveira JC.
        Low overall survival in women with de novo metastatic breast cancer: does this reflect tumor biology or a lack of access to health care?.
        JCO Global Oncol. 2020; : 679-687https://doi.org/10.1200/JGO.19.00408
        • Shen T
        • Siegal GP
        • Wei S.
        Clinicopathologic factors associated with de novo metastatic breast cancer.
        Pathol - Res Pract. 2016; 212: 1167-1173https://doi.org/10.1016/j.prp.2016.09.007
        • File DM
        • Pascual T
        • Deal AM
        • Wheless A
        • Dees EC
        • Carey LA.
        The contribution of clinical subtype to survival differences among patients with de novo and recurrent metastatic breast cancer (dMBC).
        J Clin Oncol. 2020; 38: 1030https://doi.org/10.1200/JCO.2020.38.15_suppl.1030
        • Cortesi L
        • Toss A
        • Cirilli C
        • et al.
        Twenty-years experience with de novo metastatic breast cancer: De novo metastatic breast cancer.
        Int J Cancer. 2015; 137: 1417-1426https://doi.org/10.1002/ijc.29503
        • Tripathy D
        • Brufsky A
        • Cobleigh M
        • et al.
        De Novo versus recurrent HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from the SystHERs Registry.
        Oncologist. 2020; 25: e214-e222https://doi.org/10.1634/theoncologist.2019-0446
        • Lobbezoo DJA
        • van Kampen RJW
        • Voogd AC
        • et al.
        Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?.
        Br J Cancer. 2015; 112: 1445-1451https://doi.org/10.1038/bjc.2015.127
        • Partridge AH
        • Hughes ME
        • Ottesen RA
        • et al.
        The effect of age on delay in diagnosis and stage of breast cancer.
        Oncologist. 2012; 17: 775-782https://doi.org/10.1634/theoncologist.2011-0469
        • Anders CK
        • Fan C
        • Parker JS
        • et al.
        Breast Carcinomas Arising at a Young Age: Unique Biology or a Surrogate for Aggressive Intrinsic Subtypes?.
        J Clin Oncol. 2011; 29: e18-e20https://doi.org/10.1200/JCO.2010.28.9199
        • Ogiya R
        • Sagara Y
        • Niikura N
        • Freedman RA.
        Impact of subtype on survival of young patients with Stage IV breast cancer.
        Clin Breast Cancer. 2019; 19: 200-207.e1https://doi.org/10.1016/j.clbc.2019.01.005
        • Anders CK
        • Acharya CR
        • Hsu DS
        • et al.
        Age-Specific Differences in Oncogenic Pathway Deregulation Seen in Human Breast Tumors. Wu X, ed.
        PLoS One. 2008; 3: e1373https://doi.org/10.1371/journal.pone.0001373
        • Azim HA
        • Partridge AH.
        Biology of breast cancer in young women.
        Breast Cancer Res. 2014; 16: 427https://doi.org/10.1186/s13058-014-0427-5
        • Azim HA
        • Michiels S
        • Bedard PL
        • et al.
        Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling.
        Clin Cancer Res. 2012; 18: 1341-1351https://doi.org/10.1158/1078-0432.CCR-11-2599
        • Morrison DH
        • Rahardja D
        • King E
        • Peng Y
        • Sarode VR.
        Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer.
        Br J Cancer. 2012; 107: 382-387https://doi.org/10.1038/bjc.2012.219
        • Liao S
        • Hartmaier RJ
        • McGuire KP
        • et al.
        The molecular landscape of premenopausal breast cancer.
        Breast Cancer Res. 2015; 17: 104https://doi.org/10.1186/s13058-015-0618-8
        • Villarreal-Garza C
        • Ferrigno AS
        • De la Garza-Ramos C
        • Barragan-Carrillo R
        • Lambertini M
        • Azim HA.
        Clinical utility of genomic signatures in young breast cancer patients: a systematic review.
        npj Breast Cancer. 2020; 6https://doi.org/10.1038/s41523-020-00188-3
        • Parker JS
        • Mullins M
        • Cheang MCU
        • et al.
        Supervised risk predictor of breast cancer based on intrinsic subtypes.
        J Clin Oncol. 2009; 27: 1160-1167https://doi.org/10.1200/JCO.2008.18.1370
        • Prat A
        • Galván P
        • Jimenez B
        • et al.
        Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.
        Clin Cancer Res. 2016; 22: 560-566https://doi.org/10.1158/1078-0432.CCR-15-0630
        • Prat A
        • Bianchini G
        • Thomas M
        • et al.
        Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.
        Clin Cancer Res. 2014; 20: 511-521https://doi.org/10.1158/1078-0432.CCR-13-0239
        • Prat A
        • Chaudhury A
        • Solovieff N
        • et al.
        Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies.
        J Clin Oncol. 2021; 39: 1458-1467https://doi.org/10.1200/JCO.20.02977
        • André F
        • Ciruelos E
        • Rubovszky G
        • et al.
        Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer.
        N Engl J Med. 2019; 380: 1929-1940https://doi.org/10.1056/NEJMoa1813904
        • Lehmann BD
        • Bauer JA
        • Chen X
        • et al.
        Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
        J Clin Invest. 2011; 121: 2750-2767https://doi.org/10.1172/JCI45014
        • Lehmann BD
        • Jovanović B
        • Chen X
        • et al.
        Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection.
        PLoS One. 2016; 11e0157368https://doi.org/10.1371/journal.pone.0157368
        • Miglietta F
        • Griguolo G
        • Guarneri V
        • Dieci MV.
        Programmed cell death ligand 1 in breast cancer: technical aspects, prognostic implications, and predictive value.
        Oncologist. 2019; 24: e1055-e1069https://doi.org/10.1634/theoncologist.2019-0197
        • Badve SS
        • Penault-Llorca F
        • Reis-Filho JS
        • et al.
        Determining PD-L1 status in patients with triple-negative breast cancer: lessons learned from IMpassion130.
        J Natl Cancer Inst. 2021; (Published online): djab121https://doi.org/10.1093/jnci/djab121
        • Lambertini M
        • Goldrat O
        • Ferreira AR
        • et al.
        Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.
        Ann Oncol. 2018; 29: 237-243https://doi.org/10.1093/annonc/mdx639
        • Paluch-Shimon S
        • Peccatori FA.
        BRCA 1 and 2 mutation status: the elephant in the room during oncofertility counseling for young breast cancer patients.
        Ann Oncol. 2018; 29: 26-28https://doi.org/10.1093/annonc/mdx777
        • Tutt A
        • Tovey H
        • Cheang MCU
        • et al.
        Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
        Nat Med. 2018; 24: 628-637https://doi.org/10.1038/s41591-018-0009-7
        • Larsen MJ
        • Kruse TA
        • Tan Q
        • et al.
        Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling. Prokunina-Olsson L, ed.
        PLoS One. 2013; 8: e64268https://doi.org/10.1371/journal.pone.0064268
        • Lambertini M
        • Ceppi M
        • Hamy A-S
        • et al.
        Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants.
        NPJ Breast Cancer. 2021; 7: 16https://doi.org/10.1038/s41523-021-00224-w
        • Esserman L
        • Shieh Y
        • Thompson I.
        Rethinking screening for breast cancer and prostate cancer.
        JAMA. 2009; 302: 1685-1692https://doi.org/10.1001/jama.2009.1498
        • Bleyer A
        • Welch HG.
        Effect of three decades of screening mammography on breast-cancer incidence.
        N Engl J Med. 2012; 367: 1998-2005https://doi.org/10.1056/NEJMoa1206809
        • Garrido-Castro AC
        • Spurr LF
        • Hughes ME
        • et al.
        Genomic characterization of de novo metastatic breast cancer.
        Clin Cancer Res. 2020; (Published online)https://doi.org/10.1158/1078-0432.CCR-20-1720
        • Li Y
        • Jin K
        • van Pelt GW
        • et al.
        c-Myb enhances breast cancer invasion and metastasis through the Wnt/β-Catenin/Axin2 pathway.
        Cancer Res. 2016; 76: 3364-3375https://doi.org/10.1158/0008-5472.CAN-15-2302
        • Seltzer S
        • Corrigan M
        • O'Reilly S
        The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer.
        Exp Mol Pathol. 2020; 114104404https://doi.org/10.1016/j.yexmp.2020.104404
        • Bardia A
        • Hurvitz S.
        Targeted therapy for premenopausal women with HR + , HER2 advanced breast cancer: focus on special considerations and latest advances.
        Clin Cancer Res. 2018; 24: 5206-5218https://doi.org/10.1158/1078-0432.CCR-18-0162
        • Kim HK
        • Lee S-H
        • Kim YJ
        • et al.
        Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
        BMC Cancer. 2019; 19: 84https://doi.org/10.1186/s12885-018-5258-9
        • Tripathy D
        • Im S-A
        • Colleoni M
        • et al.
        Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
        Lancet Oncol. 2018; 19: 904-915https://doi.org/10.1016/S1470-2045(18)30292-4
        • Slamon DJ
        • Neven P
        • Chia S
        • et al.
        Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
        J Clin Oncol. 2018; 36: 2465-2472https://doi.org/10.1200/JCO.2018.78.9909
        • Cristofanilli M
        • Turner NC
        • Bondarenko I
        • et al.
        Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
        Lancet Oncol. 2016; 17: 425-439https://doi.org/10.1016/S1470-2045(15)00613-0
        • Finn RS
        • Martin M
        • Rugo HS
        • et al.
        Palbociclib and Letrozole in Advanced Breast Cancer.
        N Engl J Med. 2016; 375: 1925-1936https://doi.org/10.1056/NEJMoa1607303
        • Goetz MP
        • Toi M
        • Campone M
        • et al.
        MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
        J Clin Oncol. 2017; 35: 3638-3646https://doi.org/10.1200/JCO.2017.75.6155
        • Sledge GW
        • Toi M
        • Neven P
        • et al.
        MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
        J Clin Oncol. 2017; 35: 2875-2884https://doi.org/10.1200/JCO.2017.73.7585
        • Schettini F
        • Giudici F
        • Giuliano M
        • et al.
        Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis.
        J Natl Cancer Inst. 2020; 112: 1089-1097https://doi.org/10.1093/jnci/djaa071
        • Park YH
        • Kim T-Y
        • Kim GM
        • et al.
        Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
        Lancet Oncol. 2019; 20: 1750-1759https://doi.org/10.1016/S1470-2045(19)30565-0
        • Robson M
        • Im S-A
        • Senkus E
        • et al.
        Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
        N Engl J Med. 2017; 377: 523-533https://doi.org/10.1056/NEJMoa1706450
        • Litton JK
        • Rugo HS
        • Ettl J
        • et al.
        Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
        N Engl J Med. 2018; 379: 753-763https://doi.org/10.1056/NEJMoa1802905
        • Robson ME
        • Tung N
        • Conte P
        • et al.
        OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
        Ann Oncol. 2019; 30: 558-566https://doi.org/10.1093/annonc/mdz012
        • Litton JK
        • Hurvitz SA
        • Mina LA
        • et al.
        Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
        Ann Oncol. 2020; 31: 1526-1535https://doi.org/10.1016/j.annonc.2020.08.2098
        • Diéras V
        • Han HS
        • Kaufman B
        • et al.
        Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2020; 21: 1269-1282https://doi.org/10.1016/S1470-2045(20)30447-2
        • Tung NM
        • Robson ME
        • Ventz S
        • et al.
        TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes.
        J Clin Oncol. 2020; 38: 4274-4282https://doi.org/10.1200/JCO.20.02151
        • Schmid P
        • Adams S
        • Rugo HS
        • et al.
        Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
        N Engl J Med. 2018; 379: 2108-2121https://doi.org/10.1056/NEJMoa1809615
        • Cortes J
        • Cescon DW
        • Rugo HS
        • et al.
        Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
        Lancet. 2020; 396: 1817-1828https://doi.org/10.1016/S0140-6736(20)32531-9
        • Poggio F
        • Lambertini M
        • de Azambuja E.
        Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?.
        ESMO Open. 2018; 3https://doi.org/10.1136/esmoopen-2018-000324
        • Khan SA
        • Stewart AK
        • Morrow M.
        Does aggressive local therapy improve survival in metastatic breast cancer?.
        Surgery. 2002; 132 (discussion 626-627): 620-626https://doi.org/10.1067/msy.2002.127544
        • Ruiterkamp J
        • Ernst MF
        • van de Poll-Franse LV
        • Bosscha K
        • Tjan-Heijnen VCG
        • Voogd AC.
        Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis.
        Eur J Surg Oncol. 2009; 35: 1146-1151https://doi.org/10.1016/j.ejso.2009.03.012
        • Dominici L
        • Najita J
        • Hughes M
        • et al.
        Surgery of the primary tumor does not improve survival in stage IV breast cancer.
        Breast Cancer Res Treat. 2011; 129: 459-465https://doi.org/10.1007/s10549-011-1648-2
        • Fields RC
        • Jeffe DB
        • Trinkaus K
        • et al.
        Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis.
        Ann Surg Oncol. 2007; 14: 3345-3351https://doi.org/10.1245/s10434-007-9527-0
        • Petrelli F
        • Barni S.
        Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression.
        Med Oncol. 2012; 29: 3282-3290https://doi.org/10.1007/s12032-012-0310-0
        • Khan SA
        • Zhao F
        • Solin LJ
        • et al.
        A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).
        J Clin Oncol. 2020; 38: LBA2https://doi.org/10.1200/JCO.2020.38.18_suppl.LBA2
        • Badwe R
        • Hawaldar R
        • Nair N
        • et al.
        Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.
        Lancet Oncol. 2015; 16: 1380-1388https://doi.org/10.1016/S1470-2045(15)00135-7
        • Soran A
        • Ozmen V
        • Ozbas S
        • et al.
        Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01.
        Ann Surg Oncol. 2018; 25: 3141-3149https://doi.org/10.1245/s10434-018-6494-6
        • F F
        • V B-R
        • M K
        • et al.
        Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial.
        Ann Surg. 2019; 269: 1163-1169https://doi.org/10.1097/sla.0000000000002771
        • Coates AS
        • Hürny C
        • Peterson HF
        • et al.
        Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group.
        J Clin Oncol. 2000; 18: 3768-3774https://doi.org/10.1200/JCO.2000.18.22.3768
        • Jacobsen PB
        • Nipp RD
        • Ganz PA.
        Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment.
        Am Soc Clin Oncol Educ Book. 2017; 37: 674-683https://doi.org/10.1200/EDBK_175673
        • Butler LD
        • Koopman C
        • Classen C
        • Spiegel D.
        Traumatic stress, life events, and emotional support in women with metastatic breast cancer: cancer-related traumatic stress symptoms associated with past and current stressors.
        Health Psychol. 1999; 18: 555-560https://doi.org/10.1037//0278-6133.18.6.555
        • Morrow PK
        • Broxson AC
        • Munsell MF
        • et al.
        Effect of age and race upon quality of life of young breast cancer survivors.
        Clin Breast Cancer. 2014; 14: e21-e31https://doi.org/10.1016/j.clbc.2013.10.003
        • Avis NE
        • Levine B
        • Naughton MJ
        • Case DL
        • Naftalis E
        • Van Zee KJ.
        Explaining age-related differences in depression following breast cancer diagnosis and treatment.
        Breast Cancer Res Treat. 2012; 136: 581-591https://doi.org/10.1007/s10549-012-2277-0
        • Warren M.
        Uncertainty, lack of control and emotional functioning in women with metastatic breast cancer: a review and secondary analysis of the literature using the critical appraisal technique.
        Eur J Cancer Care (Engl). 2010; 19: 564-574https://doi.org/10.1111/j.1365-2354.2010.01215.x
        • Ruddy KJ
        • Gelber SI
        • Tamimi RM
        • et al.
        Prospective study of fertility concerns and preservation strategies in young women with breast cancer.
        J Clin Oncol. 2014; 32: 1151-1156https://doi.org/10.1200/JCO.2013.52.8877
        • Perachino M
        • Massarotti C
        • Razeti MG
        • et al.
        Gender-specific aspects related to type of fertility preservation strategies and access to fertility care.
        ESMO Open. 2020; 5e000771https://doi.org/10.1136/esmoopen-2020-000771
        • Anderson RA
        • Amant F
        • et al.
        • The ESHRE Guideline Group on Female Fertility Preservation
        ESHRE guideline: female fertility preservation†.
        Hum Repro Open. 2020; (2020(hoaa052))https://doi.org/10.1093/hropen/hoaa052
        • Kangas M
        • Henry JL
        • Bryant RA.
        Posttraumatic stress disorder following cancer. A conceptual and empirical review.
        Clin Psychol Rev. 2002; 22: 499-524https://doi.org/10.1016/s0272-7358(01)00118-0
        • Mustafa M
        • Carson-Stevens A
        • Gillespie D
        • Edwards AGK.
        Psychological interventions for women with metastatic breast cancer.
        Cochrane Database Syst Rev. 2013; CD004253https://doi.org/10.1002/14651858.CD004253.pub4
        • Ganz P
        • Bower JE AH
        • Partridge AH
        Targeting depressive symptoms in younger breast cancer survivors: A randomized controlled trial of mindfulness meditation and survivorship education.
        San Antonio Breast Cancer Symopsium. 2020; (Abstract GS2-10)
        • Harbeck N
        • Franke F
        • Villanueva-Vazquez R
        • et al.
        Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7).
        Ther Adv Med Oncol. 2020; 121758835920943065https://doi.org/10.1177/1758835920943065
        • Lee S
        • Im S-A
        • Kim GM
        • et al.
        Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10).
        Cancers (Basel). 2020; 12https://doi.org/10.3390/cancers12113265
        • Rosenberg SM
        • Partridge AH.
        Premature menopause in young breast cancer: effects on quality of life and treatment interventions.
        J Thorac Dis. 2013; 5: S55-S61https://doi.org/10.3978/j.issn.2072-1439.2013.06.20
        • Linkeviciute A
        • Buonomo B
        • Fazio N
        • Spada F
        • Peccatori FA.
        Discussing motherhood when the oncological prognosis is dire: ethical considerations for physicians.
        ESMO Open. 2020; 5https://doi.org/10.1136/esmoopen-2020-000956
        • Franzoi MA
        • Agostinetto E
        • Perachino M
        • et al.
        Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer.
        Lancet Oncol. 2021; 22: e303-e313https://doi.org/10.1016/S1470-2045(20)30666-5